AVITA Medical is a regenerative medicine company focused on the development and commercialization of innovative therapies with the power to transform lives. Harnessing the regenerative properties of a patient’s own skin, AVITA Medical’s RECELL® System was approved by the U.S. Food and Drug Administration (FDA) in September 2018.
The RECELL® System is the first new PMA-approved treatment in more than 20 years for acute thermal burn wounds.
We’re elevating the standard of care for the treatment of skin restoration.
We’re exploring the potential of this novel technology platform to harness the regenerative properties of a patient’s own skin across a number of dermatological indications.
At AVITA Medical, patients are at the center of what we do. They guide and inspire our tireless dedication to advance bold innovation in regenerative medicine to deliver medical outcomes that transform lives.
PRESS RELEASE | JUNE 29, 2021
AVITA Medical Announces Inclusion in the Russell 3000 Index
PRESS RELEASE | JUNE 15, 2021
AVITA Medical Announces Preliminary Fourth Quarter 2021 Financial Results